Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
IDEAYA Biosciences, Inc. terminated Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfi (effective 2023-05-12).
- Action
- termination
- Agreement
- collaboration
- Counterparty
- Pfizer Inc.
- Value
- terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfi
- Effective
- 2023-05-12
Exact text from the filing
Amendment No. 1 additionally terminates the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Third Pfizer Agreement”) between the Company and Pfizer relating to Pfizer’s supply of crizotinib in support of the Company’s potential Phase 1 clinical trial to evaluate darovasertib in combination with crizotinib in cMET driven tumors such as non-small cell lung cancer and/or hepatocellular carcinoma.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
IDEAYA Biosciences, Inc. amended Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi (effective 2023-05-12).
- Action
- amendment
- Agreement
- collaboration
- Counterparty
- Pfizer Inc.
- Value
- increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi
- Effective
- 2023-05-12
Exact text from the filing
On May 16, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced that on May 12, 2023 it had entered into an Amendment No. 4 (“Amendment No. 4”) to the Clinical Trial Collaboration and Supply Agreement dated March 11, 2020 (the “Pfizer Agreement”) between the Company and Pfizer Inc. (“Pfizer”) relating to Pfizer’s supply of its investigational cMET inhibitor, crizotinib, in support of the Company’s ongoing Phase 1/2 clinical trial evaluating the Company’s investigational small molecule protein kinase C, or PKC, inhibitor darovasertib in combination with crizotinib in metastatic uveal melanoma, or MUM, patients.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
IDEAYA Biosciences, Inc. amended Clinical Trial Collaboration and Supply Agreement with Pfizer Inc. valued at increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi (effective 2023-05-12).
- Action
- amendment
- Agreement
- collaboration
- Counterparty
- Pfizer Inc.
- Value
- increase the defined quantity of crizotinib provided by Pfizer to the Company at no cost and to defi
- Effective
- 2023-05-12
Exact text from the filing
Additionally, on May 16, 2023, the Company announced that on May 12, 2023 it had entered into an Amendment No. 1 (“Amendment No. 1”) to the Clinical Trial Collaboration and Supply Agreement dated March 9, 2022 (the “Second Pfizer Agreement”) between the Company and Pfizer relating to Pfizer’s supply of crizotinib in support of the Company’s planned potential registration-enabling Phase 2/3 clinical trial evaluating darovasertib in combination with crizotinib in HLA-A2(-) MUM patients.
View on SEC.gov